State-owned pharmaceutical company PT Indofarma has responded to its subsidiary PT Indofarma Global Mendika which was declared in default or bankrupt by the court, assuring stability of operations in the parent company and other subsidiaries.
Hilda Yani, Corporate Secretary of Indofarma, said that this decision was the result of a creditor vote on the peace proposal submitted by Indofarma Global Medika. This decision is part of the legal process that has been carried out in compliance with regulations in Indonesia.
She said that as part of the company’s commitment, Indofarma is trying to maintain stability and sustainability both in the parent company and other subsidiaries. She ensured that the bankruptcy status of Indofarma Global Medika would not affect the operations of the parent company, namely Indofarma as a whole.
“Indofarma continues to carry out production, distribution, and health service activities as they should, while prioritizing the quality and availability of products for the community,” Hilda, on Thursday, February 13, 2025.
She said further that Indofarma will continue to communicate openly and transparently. The company will also implement the court’s decision in accordance with applicable provisions and regulations.
Indofarma is also committed to maintaining business sustainability responsibly and maintaining the trust of customers, business partners and other stakeholders.
Previously, Indofarma Global Medika was officially declared bankrupt. Through a court decision granted, appointing Sutarno as Supervisory Judge at the Central Jakarta District Court. And appointing four curator teams to handle the company’s bankruptcy process.
Meanwhile, the State-Owned Enterprises (SOEs) Health Workers Union had asked the Indonesian Attorney General’s Office to immediately seize assets belonging to the suspect in the fraud case at Indofarma.
The demand came after the Jakarta Provincial Prosecutor’s Office named former Indofarma President Director Arief Pramuhanto and two other people as suspects in a case of alleged corruption in financial management in 2020-2023. The three were named after causing losses to state-owned enterprises worth Rp371 billion.
Ridwan Kamil, Secretary General of the Federation of Health State Owned Enterprise Workers Unions, said Indofarma was unhealthy due to inefficiency for seven years. The determination of the three suspects strengthens the suspicion of corruption practices.
“We have revealed this in Commission VI of the House of Representatives (DPR). Inefficiency occurs because of corruption,” Kamil said in September 2024.
